NIDA Multimedia - Medical and Health Professionals

COVID-19 and Addiction | What Can Family and Friends Do to Help?

NIDA Director Dr. Nora Volkow talks about the significance of social support during the COVID-19 pandemic and what people can do to help loved ones in recovery or struggling with addiction.

Coping with COVID-19 and Substance Use Disorder (SUD)

NIDA Director Dr. Nora Volkow discusses the challenges faced by those in recovery or struggling with addiction and NIH research dedicated to understanding SUD-related health risks during the COVID-19 pandemic.

Overdose Prevention Education for Clinicians Treating Patients with Opioids for Chronic Pain

Treating patients with opioids for chronic pain has its built-in challenges including the risk of development of opioid use disorder and overdose. The importance of a dynamic, patient centered approach to the management of these challenges cannot be stressed enough given the doubling of opioid related overdose deaths in the US over the past decade. This brief NIDA video provides strategies for avoiding development of opioid use disorder as well as overdose prevention through identification of an individual’s risk, safety planning and overdose rescue preparation.

Overdose Prevention Education for Clinicians Treating Patients for an Opioid Use Disorder

Given the doubling of opioid related overdose deaths in the US over the past decade the importance of a dynamic, patient centered approach to opioid overdose risk for patients in treatment for opioid use disorder cannot be stressed enough. This brief NIDA video provides strategies for overdose prevention through identification of an individual’s risk factors, stressing the importance of treatment adherence, safety planning and overdose rescue preparation.

Adolescent Substance Use Screening tools in Primary Care Settings

In this short video, Dr. Geetha Subramaniam from the National Institute on Drug Abuse (NIDA) discusses the differences between BSTAD and S2BI and how a provider can choose which of the two tools to use. She also explains the difference between universal and targeted screening, and shares information about considerations for confidentiality among teen patients.